Lyell Q4 net loss $191.9M; cash $383.5M; IMPT-314 pivotal trials set for mid-2025, early 2026

Lyell Immunopharma, Inc.

Net loss of $191.9M in Q4 2024 included $87.2M acquired IPR&D from ImmPACT Bio and $51.3M long-lived asset impairment.
Cash, equivalents and marketable securities of $383.5M at Dec 31, 2024; expected to fund operations into 2027.
IMPT-314 Phase 1/2 showed 94% ORR (16/17) and 71% complete response by 3 months; no Grade 3+ CRS in 23 patients.
Pivotal trial for IMPT-314 in 3rd line+ LBCL expected mid-2025; 2nd line pivotal expected by early 2026.
Non-GAAP net loss Q4 2024 was $45.9M vs $43.9M in Q4 2023; full year 2024 non-GAAP net loss $159.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.